Aims: The metabolic syndrome (MetS) is composed of a cluster of related cardiovascular risk factors. The aim of the present study was to determine how MetS contributes to short-(30-day) and long-term complications and restenosis after carotid endarterectomy (CEA) or stenting (CAS).
| INTRODUCTION
The metabolic syndrome (MetS) is composed of a cluster of related cardiovascular risk factors including hypertension, obesity, and a prediabetic state, which is manifested by high fasting serum blood glucose, high triglycerides, and low levels of high-density lipoprotein (HDL). 1 The prevalence of MetS is increasing rapidly in the Western world. 2 It is estimated that MetS currently affects between 9% and 35% of the overall population depending on populations studied and MetS definition employed. 3, 4 Prior studies have shown a two-fold higher risk of developing cardiovascular disease and a 1.5-fold increased risk of all-cause mortality in patients with MetS compared with patients without MetS. 5 Consequently, there has been a growing interest in the association between MetS and cardiovascular diseases. People with MetS had both increased mortality from cardiovascular diseases (12.0% vs 2.2%) and increased total mortality (18.0% vs 4.6%) compared with those without MetS. 4 Various studies have shown an increased incidence and more rapid progression of carotid atherosclerosis in patients with MetS, 6 in both men 7 and women. 8, 9 The presence of MetS is associated with an amplified vascular wall thickness and stiffness 10, 11 and an overall prothrombotic state. 12 Carotid endarterectomy (CEA) is the current gold standard therapy for carotid artery stenosis caused by atheromatous narrowing at the carotid bifurcation. 13, 14 Carotid artery stenting (CAS) is emerging as a less invasive technique than CEA, especially for subjects at increased surgical risk, and has clinical results comparable with surgery at preventing stroke in the long term (>30 days). [15] [16] [17] [18] [19] Despite these observations, few studies have investigated the role of MetS on postprocedural complications after carotid revascularization, reporting conflicting results on survival, major adverse events (MAE), and restenosis. [20] [21] [22] In this study, a consecutive cohort of patients undergoing CEA or CAS in a single institution has been examined to determine how MetS contributes to short-(ie, 30-day postprocedure) and long-term complications and restenosis following carotid revascularization. and (4) renal insufficiency (creatinine ≥1.5 mg/dL). 24 
| Procedures
For CEA, patients were usually maintained on aspirin therapy, and CEA was performed under local anaesthesia with electroencephalography or transcutaneous oxygen saturation monitoring. Both dacron or bovine pericardium graft angioplasty and eversion endarterectomy were performed.
For CAS, dual antiplatelet therapy was started 1 day before the procedure. All patients received a 300-mg loading dose of clopidogrel 1 hour before the procedure. The carotid stenting procedure has been described previously. 25 All procedures were performed following a standardized protocol in the operating room, equipped with a portable imaging fluoroscopic C-arm (OEC 9900 elite; GE Medical Siemens, After both CAS and CEA, patients were followed by carotid DUS of the supraaortic vessels at 30 days and then 3, 6, and 12 months and yearly thereafter for 3 years, and symptom status was assessed by a vascular surgeon.
| Definitions
There are multiple definitions of MetS. 1, 28, 29 In the present study, A MAE was defined as the occurrence of a minor or major ipsilateral stroke, myocardial infarction (MI) or death during the follow-up period. Neurological deficits that resolved completely within 30 days or those that did not lead to functional impairment in daily activities (as assessed by the vascular surgeon) were defined as minor strokes. All other strokes were considered major strokes.
The diagnosis and quantification of restenosis were performed using carotid DUS. Carotid restenosis was set at ≥50%, according to DUS velocity criteria equivalent to NASCET angiography measures used for grading the degree of carotid stenosis. 13 Short-term was defined as a complication occurring during the hospital admission and less than 30 days after the procedure. Longterm was defined as a complication occurring more than 30 days after the procedure.
| Statistical analysis
Measured values are presented as percentages or mean ± standard deviation (SD). Rates for demographic and baseline characteristics, components of MetS, and short-and long-term outcomes were compared between patients with and without MetS and between those undergoing CAS and CEA by χ 2 test. Survival, major and minor stroke, MAE, and restenosis rates were calculated using Kaplan-Meier analysis to compensate for patient dropouts and are reported using current Society for Vascular Surgery (SVS) criteria. 31 Standard errors (SE) are reported in Kaplan-Meier analyses. The log-rank test was used to determine differences among patients with and without MetS submitted to CEA and CAS. The Cox proportional hazard models were used to examine the associations between MetS and freedom from MAE, and freedom from restenosis, and between the components of MetS and death, MAE, and restenosis.
A value of p < 0.05 was considered statistically significant for all measurements. All analyses were performed using STATA (STATA Corp, version 14.0, College Station, Texas).
| Ethics
Written consent was obtained from all patients before both CAS and CEA revascularization. The study was approved by the local ethic committee of this institution.
3 | RESULTS Of the 752 carotid revascularization, procedures 314 (41.8%) were by CEA and 438 (58.2%) were by CAS. The distribution of comorbidities differed considerably between the two procedural groups. The CAS group had a greater proportion of smokers, patients with hyperlipidaemia, chronic renal insufficiency, and congestive heart failure (CHF) compared with the CEA group. The CEA group had a greater proportion of patients with diabetes and history of MI (Table 1A) .
| Study cohort
Of the five criteria used to define MetS, hypertension was the most prevalent among the patients with a rate of 86.3% and 77.9%
in patients with and without MetS (Table 1B) .
| Outcomes
Short-and long-term surveillance included DUS and neurological examination at 30-day postprocedure; 3, 6, 12 months; and then yearly. The 30-day all-cause mortality rate was 0.3% (two deaths). Similarly, there were no differences in rates of MAE during followup among patients with and without MetS undergoing CEA or CAS. At 36 months, patients without MetS experienced a higher death rate, but this was not statistically significant (9.2% vs 6.9%, p = 0.08) ( Table 2 ).
| Procedural differences

| Hazard analysis
Cox proportional hazard analysis showed that none of the variables were independently predictive of long-term freedom from MAE (Table 3) , while MetS was the only factor that independently predicted restenosis (Table 4) .
Interestingly, among the components of MetS, high fasting serum glucose (≥110.0 mg/dL) was the only factor that independently predicted short-and long-term mortality (Table S1 ) and restenosis (Table S3) ) were found to be significantly associated with risk of MAE (Table S2 ). Hypertension and elevated triglycerides were not proven to be of predictive value for both short-and long-term complications after CEA and CAS.
| DISCUSSION
In this study, the impact of MetS on short-and long-term outcomes after carotid revascularization for both symptomatic and asymptomatic diseases has been systematically analysed in 752 patients.
Patients with MetS had a significant increased risk in their 30-day death, MAE, and restenosis rates, both after CEA and after CAS. The MAE and restenosis rate remained statistically different during longterm clinical follow-up for both procedures. The presence of MetS was also associated with a significantly higher rate of restenosis.
MetS is being increasingly recognized as an important risk factor for cardiovascular diseases. In the last decade, increasing attention has been paid in the investigation on the association between this reported to be associated with higher long-term cardiovascular event rate, but 30-day complication rate does not significantly increased in patients with MetS after CAS. 20 These previous studies found that
MetS should be considered a significant risk factor for MAE and restenosis for patients undergoing carotid revascularization. The present study includes a large cohort of patients undergoing CAS procedures for carotid revascularization and hence may be more generalizable than previously published studies.
MetS represents a constellation of factors that, individually, are well-known cardiovascular risk factors, including diabetes and lipid abnormalities, which have previously been suggested to affect the durability of CEA and CAS. The effect of diabetes on CEA and CAS outcomes has been previously examined. The CREST (Carotid Revascularization Endarterectomy vs Stenting Trial) study reported that diabetes, along with hypertension and dyslipidaemia, were independent predictors of restenosis or occlusion after both CEA and CAS procedures within 2 years. 33 Patients with a pre-existing diagnosis of diabetes increased three-fold the risk of perioperative death after CEA and were slightly more likely to have restenosis at 7 years compared with patients without diabetes at 23% vs 18% respectively. Diabetes has been found to accelerate atherosclerosis and to hasten restenosis after CEA. 35 Protack and colleagues found that the presence of both diabetes and MetS was significantly associated with perioperative outcomes for carotid revascularization. 20 In the present study cohort, the presence of diabetes was associated with higher periprocedural risk of any stroke and death and higher rates of short-and long-term restenosis. Among patients with MetS, those with elevated BMI, high fasting serum glucose, and reduced HDL cholesterol had significantly increased risk of restenosis, within 3 years after carotid revascularization. Collectively, this evidence strongly suggests that the presence of a prediabetic state is an indicator of cardiovascular risk.
| Limitations
The present study is limited because it is single-centre, retrospective, and not randomized. In conclusion, patients with MetS are at a greater risk for shortterm death, MAE, and restenosis as well as MAE and restenosis during long-term follow-up compared with patients without MetS. The current study showed that the presence of MetS is an important risk factor for morbidity and restenosis after CEA and CAS; thus, more frequent and long-term surveillance might be warranted for this group of patients.
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